Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Antimicrob Agents Chemother ; 59(9): 5736-46, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26169403

ABSTRACT

Novel mechanisms of action and new chemical scaffolds are needed to rejuvenate antibacterial drug discovery, and riboswitch regulators of bacterial gene expression are a promising class of targets for the discovery of new leads. Herein, we report the characterization of 5-(3-(4-fluorophenyl)butyl)-7,8-dimethylpyrido[3,4-b]quinoxaline-1,3(2H,5H)-dione (5FDQD)-an analog of riboflavin that was designed to bind riboswitches that naturally recognize the essential coenzyme flavin mononucleotide (FMN) and regulate FMN and riboflavin homeostasis. In vitro, 5FDQD and FMN bind to and trigger the function of an FMN riboswitch with equipotent activity. MIC and time-kill studies demonstrated that 5FDQD has potent and rapidly bactericidal activity against Clostridium difficile. In C57BL/6 mice, 5FDQD completely prevented the onset of lethal antibiotic-induced C. difficile infection (CDI). Against a panel of bacteria representative of healthy bowel flora, the antibacterial selectivity of 5FDQD was superior to currently marketed CDI therapeutics, with very little activity against representative strains from the Bacteroides, Lactobacillus, Bifidobacterium, Actinomyces, and Prevotella genera. Accordingly, a single oral dose of 5FDQD caused less alteration of culturable cecal flora in mice than the comparators. Collectively, these data suggest that 5FDQD or closely related analogs could potentially provide a high rate of CDI cure with a low likelihood of infection recurrence. Future studies will seek to assess the role of FMN riboswitch binding to the mechanism of 5FDQD antibacterial action. In aggregate, our results indicate that riboswitch-binding antibacterial compounds can be discovered and optimized to exhibit activity profiles that merit preclinical and clinical development as potential antibacterial therapeutic agents.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cecum/microbiology , Clostridioides difficile/drug effects , Enterocolitis, Pseudomembranous/drug therapy , Flavin Mononucleotide/therapeutic use , Flavins/therapeutic use , Animals , Clostridioides difficile/pathogenicity , Female , Mice , Mice, Inbred C57BL , Riboswitch
2.
Curr Top Med Chem ; 4(10): 1097-114, 2004.
Article in English | MEDLINE | ID: mdl-15193141

ABSTRACT

The past decade has seen many exciting achievements and advances in the treatment of HIV infection. One of the key components in this ever-evolving remedial strategy has been medicinally efficacious enzymatic inhibitors targeting the essential viral aspartyl protease. While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance. In addition, the development of and selection for resistant mutants have limited the long-term therapeutic outlook of the current protease inhibitors. The need for complementary agents in this salutary class addressing these challenges and opportunities is vividly clear. To this end, much attention and focus has been placed on cyclic, non-peptidic protease inhibitors, exemplified by dihydropyrones and ureas, and their possible future role in this medicinal campaign. The strategies to their design as well as their biological, pharmacokinetic and resistance profiles, and their clinical application will be discussed.


Subject(s)
Anti-HIV Agents/chemistry , HIV Protease Inhibitors/chemistry , Urea/analogs & derivatives , Anti-HIV Agents/pharmacokinetics , Anti-HIV Agents/pharmacology , Disulfides/chemistry , Disulfides/pharmacology , Drug Resistance, Viral/genetics , Furans/chemistry , Furans/pharmacology , HIV/drug effects , HIV/genetics , HIV Infections/drug therapy , HIV Protease Inhibitors/pharmacokinetics , HIV Protease Inhibitors/pharmacology , Heterocyclic Compounds, 4 or More Rings/chemistry , Heterocyclic Compounds, 4 or More Rings/pharmacology , Humans , Molecular Structure , Mutation , Pyridines/chemistry , Pyridines/pharmacology , Pyrones/chemistry , Pyrones/pharmacokinetics , Pyrones/pharmacology , Pyrones/therapeutic use , Sulfonamides/chemistry , Sulfonamides/pharmacokinetics , Sulfonamides/pharmacology , Triazines/chemistry , Triazines/pharmacology , Urea/chemistry , Urea/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...